717 related articles for article (PubMed ID: 25621840)
1. Designing chimeric antigen receptors to effectively and safely target tumors.
Jensen MC; Riddell SR
Curr Opin Immunol; 2015 Apr; 33():9-15. PubMed ID: 25621840
[TBL] [Abstract][Full Text] [Related]
2. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
4. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
6. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
7. The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.
DeRenzo C; Krenciute G; Gottschalk S
Am Soc Clin Oncol Educ Book; 2018 May; 38():830-837. PubMed ID: 30231350
[TBL] [Abstract][Full Text] [Related]
8. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC; Riddell SR
Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
[TBL] [Abstract][Full Text] [Related]
9. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.
Maus MV; June CH
Clin Cancer Res; 2016 Apr; 22(8):1875-84. PubMed ID: 27084741
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
13. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
14. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.
Valton J; Guyot V; Marechal A; Filhol JM; Juillerat A; Duclert A; Duchateau P; Poirot L
Mol Ther; 2015 Sep; 23(9):1507-18. PubMed ID: 26061646
[TBL] [Abstract][Full Text] [Related]
15. New Strategies for the Treatment of Solid Tumors with CAR-T Cells.
Zhang H; Ye ZL; Yuan ZG; Luo ZQ; Jin HJ; Qian QJ
Int J Biol Sci; 2016; 12(6):718-29. PubMed ID: 27194949
[TBL] [Abstract][Full Text] [Related]
16. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
17. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
18. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
[TBL] [Abstract][Full Text] [Related]
19. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell therapy: 25years in the making.
Gill S; Maus MV; Porter DL
Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]